Daily Cardiology Research Analysis
Analyzed 96 papers and selected 3 impactful papers.
Summary
Analyzed 96 papers and selected 3 impactful articles.
Selected Articles
1. Second-Generation Aldosterone Synthase Inhibitors for Hypertension: A Bayesian Meta-Analysis of Randomized Trials.
Across 8 RCTs (n=3,371), second-generation aldosterone synthase inhibitors lowered systolic blood pressure by a mean 6.7 mmHg versus placebo using a Bayesian framework. Safety analyses indicated higher odds of hyperkalemia, hyponatremia, and hypotension compared with placebo.
Impact: This analysis consolidates the antihypertensive efficacy of a novel drug class with transparent Bayesian estimates and registration, while simultaneously quantifying predictable mineralocorticoid-related adverse events.
Clinical Implications: Aldosterone synthase inhibitors may become valuable options for resistant or difficult-to-treat hypertension, but require careful electrolyte monitoring and hypotension surveillance. Longer-term outcome trials are needed to define effects on cardiovascular events.
Key Findings
- Pooled Bayesian analysis of 8 RCTs (n=3,371) showed a mean SBP reduction of −6.7 mmHg versus placebo.
- Adverse events including hyperkalemia, hyponatremia, and hypotension occurred more frequently with ASIs.
- Protocol was prospectively registered (PROSPERO CRD420251132306), supporting methodological transparency.
Methodological Strengths
- Prospectively registered protocol with Bayesian random-effects and hierarchical safety modeling
- Exclusive inclusion of randomized controlled trials across multiple agents (baxdrostat, lorundrostat, vicadrostat)
Limitations
- Heterogeneity in dosing regimens and trial designs; limited reporting of long-term cardiovascular outcomes
- Safety signals require confirmation in larger and longer-duration studies with standardized monitoring
Future Directions: Conduct large, event-driven RCTs to test cardiovascular outcomes; define patient subgroups (e.g., CKD, resistant hypertension) with optimal benefit-risk; develop monitoring protocols to mitigate electrolyte disturbances.
BACKGROUND: Second-generation aldosterone-synthase inhibitors (ASIs) may offer a novel treatment for hypertension. OBJECTIVES: The objective of the study was to assess the efficacy and safety of ASIs in this clinical setting. METHODS: We searched major databases for randomized controlled trials assessing ASIs (baxdrostat, lorundrostat, and vicadrostat) in patients with hypertension. For efficacy outcomes, mean differences (MD) with 95% credible intervals (CrIs) were estimated using a Bayesian random-effects model. For adverse events, OR with 95% CrI were estimated using a Bayesian binomial-normal hierarchical model. The protocol was registered in Prospective Register of Systematic Reviews (CRD420251132306). RESULTS: Eight randomized controlled trials were included (n = 3,371; 2,430 [72%] randomized to ASI). ASI reduced systolic blood pressure (SBP) (MD: -6.7 mm Hg; CrI: -8.78, -4.59; τ CONCLUSIONS: Second-generation ASIs had a high likelihood of a clinically significant reduction in SBP compared with placebo. However, hyperkalemia, hyponatremia, and hypotension were more frequent with ASIs.
2. Pulsed field versus thermal ablation for atrial fibrillation: A Bayesian meta-analysis.
In 12 studies (4 RCTs; n=3,120), PFA reduced atrial arrhythmia recurrence versus thermal ablation with a reconstructed time-to-event HR of 0.68 and required approximately 12 months to achieve a clinically meaningful absolute benefit. Safety signals did not show consistent excess harm, and procedure times were often shorter with PFA.
Impact: This synthesis bridges heterogeneous evidence with IPD reconstruction and Bayesian modeling, quantifying both efficacy and time-to-benefit for a rapidly adopted nonthermal ablation modality.
Clinical Implications: PFA appears to improve arrhythmia-free survival with similar safety compared with thermal ablation, supporting its adoption where expertise and technology are available. Clinicians should counsel patients that meaningful benefits accrue over ~12 months and await further head-to-head RCT confirmation.
Key Findings
- PFA was associated with lower arrhythmia recurrence versus thermal ablation (HR 0.68; 95% CrI 0.55–0.84).
- A time-to-benefit of 12 months was needed to prevent ~5 recurrences per 100 PFA-treated patients.
- Safety outcomes showed no consistent excess risk with PFA, and procedure metrics favored shorter times.
Methodological Strengths
- Reconstruction of individual patient time-to-event data from Kaplan–Meier curves with Cox frailty modeling
- Bayesian random-effects synthesis across RCTs and observational studies with assessment of time-to-benefit
Limitations
- Heterogeneity and potential biases in observational studies; modest effect sizes in RCTs
- Reliance on reconstructed IPD and variable follow-up durations limit precision and generalizability
Future Directions: Large, head-to-head RCTs with standardized endpoints should confirm efficacy, safety (including collateral injury profiles), and durability beyond 12–24 months, and define patient selection and workflow optimization.
BACKGROUND: Pulsed field ablation (PFA) has emerged as a promising alternative to thermal catheter ablation for pulmonary vein isolation in atrial fibrillation (AF). OBJECTIVES: To estimate the efficacy and safety of PFA versus thermal ablation in AF. METHODS: We searched PubMed, Embase, and Cochrane through July 2025 for studies comparing PFA with thermal ablation. Individual patient data were reconstructed from Kaplan-Meier curves, and hazard ratios (HR) were estimated using a Cox frailty regression model. Time-to-benefit was assessed to determine when the treatment effect becomes clinically meaningful. Study-level odds ratios (OR) and mean differences with 95% credible intervals (CrI) were estimated with a Bayesian random-effects model and non-informative priors for primary analyses. RESULTS: Twelve studies (4 RCTs, 8 observational) involving 3,120 patients (46.6% PFA) were included. Time-to-event analysis (1 RCT, 6 observational) showed PFA was associated with higher freedom from arrhythmia recurrence (HR 0.68; 95% CrI, 0.55-0.84). A time to benefit of 12 months was needed to prevent 5 atrial arrhythmia recurrences per 100 PFA-treated patients. In study-level analyses, the probability of a clinically meaningful reduction (OR < 0.8) in arrhythmia recurrence was 34.1% for RCTs and 96.5% for observational studies. PFA had a high likelihood of shorter procedural and left atrial dwell times. Safety outcomes showed no consistent excess risk with PFA. CONCLUSION: In patients with AF undergoing catheter ablation, PFA was associated with reduced arrhythmia recurrence compared with thermal ablation, with larger effects in observational studies and more modest effects in RCTs, and no signal of increased harm.
3. Intraosseous and intravenous vascular access during adult cardiac arrest: a systematic review and meta-analysis.
In two RCTs totaling 7,561 out-of-hospital cardiac arrest patients, intraosseous-first access did not improve 30-day survival or favorable neurological outcomes compared with intravenous-first and was associated with lower odds of sustained ROSC. Evidence certainty was graded moderate for survival and sustained ROSC.
Impact: This rigorously appraised, registered synthesis directly informs resuscitation protocols by clarifying that intraosseous-first access confers no survival advantage and may compromise sustained ROSC.
Clinical Implications: When feasible, prioritize intravenous access during OHCA; reserve intraosseous access for scenarios where IV placement is not rapidly achievable. Emphasize team training and workflow to minimize delays in medication delivery.
Key Findings
- No improvement in 30-day survival with intraosseous-first versus intravenous-first access (OR 0.97; 95% CI 0.80–1.18).
- Sustained ROSC was less likely with intraosseous-first access (OR 0.89; 95% CI 0.80–0.99).
- GRADE-rated certainty was moderate for survival and sustained ROSC; one originally included trial was retracted, leaving two RCTs.
Methodological Strengths
- Prospective registration (PROSPERO), Cochrane-compliant risk of bias and GRADE assessment
- Randomized controlled trials with large aggregate sample size and standardized outcomes
Limitations
- Only two RCTs available after retraction; fixed-effect model may underweight unexplained heterogeneity
- Findings pertain to out-of-hospital cardiac arrest and may not generalize to in-hospital settings
Future Directions: Undertake pragmatic multicenter RCTs comparing IV-first vs IO-first strategies with process metrics (time-to-drug, success rates) and neurologic outcomes; evaluate hybrid algorithms based on scene logistics.
OBJECTIVE: To summarise evidence on the clinical effectiveness of initial vascular attempts via the intraosseous route compared to the intravenous route in adult cardiac arrest. METHODS: We searched MEDLINE and Embase (OVID platform), the Cochrane library, and the International Clinical Trials Registry Platform from inception to September 4th 2024 for randomised clinical trials comparing the intraosseous route with the intravenous route in adult cardiac arrest. Our primary outcome was 30-day survival. Secondary outcomes included favourable neurological outcome at 30-days/hospital discharge and return of spontaneous circulation (both any ROSC and sustained ROSC). We performed meta-analyses using a fixed-effect model. We assessed risk of bias using the Cochrane Risk of Bias-2 tool and evidence certainty using the GRADE approach. RESULTS: We originally included three randomised clinical trials, but one trial was subsequently retracted. As such, two trials were included encompassing 7561 participants with out-of-hospital cardiac arrest. Initial attempts via the intraosseous, compared with intravenous, route did not increase the odds of 30-day survival (odds ratio 0.97, 95% confidence interval 0.80-1.18; 7540 participants; two trials; moderate-certainty evidence) or favourable neurological outcome at 30-days/hospital discharge (odds ratio 1.03, 95% confidence interval 0.81-1.31; 7454 participants; two trials; low-certainty evidence). The odds of achieving sustained return of spontaneous circulation were lower in the intraosseous group (odds ratio 0.89, 95% confidence interval 0.80-0.99; 7518 participants; two trials; moderate-certainty evidence). CONCLUSION: Initial vascular access attempts via the intraosseous, compared with intravenous, route in adult cardiac arrest did not improve 30-day survival and may reduce the odds of a sustained return of spontaneous circulation. REGISTRATION: PROSPERO CRD42024577647.